ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy
In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in resected stage I and stage II (without high risk) colorectal cancer after radical resection
| Condition(s) | Cancer Colorectal |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in resected stage I and stage II (without high risk) colorectal cancer after radical resection. |
| Who can participate | Inclusion Criteria: * Patients must have histologically confirmed stage I/II (without high risk) colorectal cancer. * Male or female ≥ 18 years of age on the day of signing informed consent. * Patients need to receive surgical resection, and with ctDNA positive prior to resection of colorectal cancer (CRC). * Patients must have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. * Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study. Exclusion Criteria: * Personal history of colorectal cancer, colorectal adenoma or aerodigestive tract cancer. * Induction of neoadjuvant systemic therapy prior to resection of CRC. * Patient is pregnant or lactati |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Singlera Genomics Inc. |
| Locations | Hangzhou, Zhejiang, China |
| Start date | 2022-09-05 |
| NCT ID | NCT05536089 |
| Official listing | https://clinicaltrials.gov/study/NCT05536089 |